Serum biomarkers in patients suspected of transient ischaemic attack in primary care: a diagnostic accuracy study

Louis Servaas Dolmans, Frans Rutten, Marie-Louise E L Bartelink, Ewoud J van Dijk, Paul J Nederkoorn, Jaap Kappelle, Arno W Hoes, MIND-TIA study group, L S Dolmans, Mel Bartelink, F H Rutten, A W Hoes, L J Kappelle, E J van Dijk, P J Nederkoorn, S van Delft, G J Seppenwoolde, Louis Servaas Dolmans, Frans Rutten, Marie-Louise E L Bartelink, Ewoud J van Dijk, Paul J Nederkoorn, Jaap Kappelle, Arno W Hoes, MIND-TIA study group, L S Dolmans, Mel Bartelink, F H Rutten, A W Hoes, L J Kappelle, E J van Dijk, P J Nederkoorn, S van Delft, G J Seppenwoolde

Abstract

Objective: The diagnosis of transient ischaemic attack (TIA) based on symptoms and signs can be challenging and would greatly benefit from a rapid serum biomarker of brain ischaemia. We aimed to quantify the added diagnostic value of serum biomarkers in patients suspected of TIA beyond symptoms and signs.

Methods: This is a cross-sectional diagnostic accuracy study with a 6-month follow-up period. Participants were patients suspected of TIA by the general practitioner (GP) in whom a blood sample could be collected within 72 hours from symptom onset. A research nurse visited the participant for the blood sample and a standardised interview. The GP referred participants to the regional TIA service. An expert panel of three neurologists classified cases as TIA, minor stroke or any other diagnosis, based on all available diagnostic information including the GP's and neurologist's correspondence and the follow-up period. We used multivariable logistic regression analyses to quantify the diagnostic accuracy of clinical predictors and the improvement of accuracy by seven biomarkers (NR2, NR2 antibodies, PARK7, NDKA, UFD1, B-FABP and H-FABP).

Results: 206 patients suspected of TIA participated, of whom 126 (61.2%) were diagnosed with TIA (n=104) or minor stroke (n=22) by the expert panel. The median time from symptom onset to the blood sample collection was 48.0 (IQR 28.3-56.8) hours. None of the seven biomarkers had discriminative value in the diagnosis of TIA, with C-statistics ranging from 0.45 to 0.58. The final multivariable model (C-statistic 0.83 (0.78-0.89)) consisted of eight clinical predictors of TIA/minor stroke: increasing age, a history of coronary artery disease, sudden onset of symptoms, occurrence of symptoms in full intensity, dysarthria, no history of migraine, absence of loss of consciousness and absence of headache. Addition of the individual biomarkers did not further increase the C-statistics.

Conclusions: Currently available blood biomarkers have no added diagnostic value in suspected TIA.

Trial registration number: NCT01954329.

Keywords: TIA; biomarker; diagnostic accuracy; minor stroke; panel.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

References

    1. Giles MF, Rothwell PM. Risk of stroke early after transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol 2007;6:1063–72. 10.1016/S1474-4422(07)70274-0
    1. Wu CM, McLaughlin K, Lorenzetti DL, et al. . Early risk of stroke after transient ischemic attack: a systematic review and meta-analysis. Arch Intern Med 2007;167:2417–22. 10.1001/archinte.167.22.2417
    1. Rothwell PM, Giles MF, Chandratheva A, et al. . Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (express study): a prospective population-based sequential comparison. The Lancet 2007;370:1432–42. 10.1016/S0140-6736(07)61448-2
    1. Lavallée PC, Meseguer E, Abboud H, et al. . A transient ischaemic attack clinic with round-the-clock access (SOS-TIA): feasibility and effects. Lancet Neurol 2007;6:953–60. 10.1016/S1474-4422(07)70248-X
    1. Rothwell PM, Algra A, Chen Z, et al. . Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. The Lancet 2016;388:365–75. 10.1016/S0140-6736(16)30468-8
    1. Moreau F, Asdaghi N, Modi J, et al. . Magnetic resonance imaging versus computed tomography in transient ischemic attack and minor stroke: the more Υou see the more you know. Cerebrovasc Dis Extra 2013;3:130–6. 10.1159/000355024
    1. Förster A, Gass A, Kern R, et al. . Brain imaging in patients with transient ischemic attack: a comparison of computed tomography and magnetic resonance imaging. Eur Neurol 2012;67:136–41. 10.1159/000333286
    1. Fonseca AC, Canhão P. Diagnostic difficulties in the classification of transient neurological attacks. Eur J Neurol 2011;18:644–8. 10.1111/j.1468-1331.2010.03241.x
    1. Amarenco P, Labreuche J, Lavallée PC. Patients with transient ischemic attack with ABCD2 <4 can have similar 90-day stroke risk as patients with transient ischemic attack with ABCD2 ≥4. Stroke 2012;43:863–5. 10.1161/STROKEAHA.111.636506
    1. Amort M, Fluri F, Schäfer J, et al. . Transient ischemic attack versus transient ischemic attack mimics: frequency, clinical characteristics and outcome. Cerebrovasc Dis 2011;32:57–64. 10.1159/000327034
    1. Dolmans LS, Kappelle LJ, Bartelink M-LE, et al. . Delay in patients suspected of transient ischaemic attack: a cross-sectional study. BMJ Open 2019;9:e027161 10.1136/bmjopen-2018-027161
    1. Dolmans LS, Rutten FH, El Bartelink M-L, et al. . Serum biomarkers for the early diagnosis of TIA: the MIND-TIA study protocol. BMC Neurol 2015;15:119 10.1186/s12883-015-0388-z
    1. Dolmans LS, Rutten FH, Koenen NCT, et al. . Candidate biomarkers for the diagnosis of transient ischemic attack: a systematic review. Cerebrovasc Dis 2019;47:207–16. 10.1159/000502449
    1. Easton JD, Saver JL, Albers GW, et al. . Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American heart Association/American stroke association stroke Council; Council on cardiovascular surgery and anesthesia; Council on cardiovascular radiology and intervention; Council on cardiovascular nursing; and the interdisciplinary Council on peripheral vascular disease. the American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke 2009;40:2276–93. 10.1161/STROKEAHA.108.192218
    1. Harrell FE, Lee KL, Califf RM, et al. . Regression modelling strategies for improved prognostic prediction. Stat Med 1984;3:143–52. 10.1002/sim.4780030207
    1. Dambinova SA, Bettermann K, Glynn T, et al. . Diagnostic potential of the NMDA receptor peptide assay for acute ischemic stroke. PLoS One 2012;7:e42362 10.1371/journal.pone.0042362
    1. Weissman JD, Khunteev GA, Heath R, et al. . NR2 antibodies: risk assessment of transient ischemic attack (TIA)/stroke in patients with history of isolated and multiple cerebrovascular events. J Neurol Sci 2011;300:97–102. 10.1016/j.jns.2010.09.023
    1. Wunderlich MT, Hanhoff T, Goertler M, et al. . Release of brain-type and heart-type fatty acid-binding proteins in serum after acute ischaemic stroke. J Neurol 2005;252:718–24. 10.1007/s00415-005-0725-z
    1. Allard L, Burkhard PR, Lescuyer P, et al. . Park7 and nucleoside diphosphate kinase A as plasma markers for the early diagnosis of stroke. Clin Chem 2005;51:2043–51. 10.1373/clinchem.2005.053942
    1. Allard L, Turck N, Burkhard PR, et al. . Ubiquitin fusion degradation protein 1 as a blood marker for the early diagnosis of ischemic stroke. Biomark Insights 2007;2:155–64. 10.1177/117727190700200033
    1. Dutta D, Diagnosis of TIA. Diagnosis of TIA (DOT) score--design and validation of a new clinical diagnostic tool for transient ischaemic attack. BMC Neurol 2016;16:20 10.1186/s12883-016-0535-1
    1. Dawson J, Lamb KE, Quinn TJ, et al. . A recognition tool for transient ischaemic attack. QJM 2009;102:43–9. 10.1093/qjmed/hcn139
    1. Lasserson DS, Chandratheva A, Giles MF, et al. . Influence of general practice opening hours on delay in seeking medical attention after transient ischaemic attack (TIA) and minor stroke: prospective population based study. BMJ 2008;337:a1569 10.1136/bmj.a1569
    1. Penn AM, Bibok MB, Saly VK, et al. . Validation of a proteomic biomarker panel to diagnose minor-stroke and transient ischaemic attack: phase 2 of spectra, a large scale translational study. Biomarkers 2018;23:793–803. 10.1080/1354750X.2018.1499130

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe